Scott Jemima K, Letts Matthew, Hajee-Adam Wafaa, Chau Hoi Man, Selman Lucy E, Caskey Fergus J, Bailey Pippa K, Ascione Raimondo, Johnson Tom, Ben-Shlomo Yoav
Bristol Medical School, Population Health Sciences, University of Bristol, Bristol, UK.
Richard Bright Renal Service, North Bristol NHS Trust, Southmead Hospital, Bristol, UK.
Cardiol Res. 2024 Dec;15(6):425-438. doi: 10.14740/cr1731. Epub 2024 Dec 3.
Coronary artery bypass grafting (CABG) provides superior long-term outcomes to percutaneous coronary intervention (PCI) for complex multivessel coronary artery disease (CAD). People with chronic kidney disease (CKD) have increased prevalence of multivessel CAD, but also increased surgical risk. We investigated whether CKD predicted real-world use of CABG, versus PCI, in patients revascularized for acute coronary syndrome (ACS).
Embase, MEDLINE, Scopus and CENTRAL were searched to identify articles referring to ACS and invasive coronary intervention in high-income countries (2012 - 2023). Articles were included if CABG rates were reported in ACS patients with and without CKD receiving revascularization. CKD was defined as an estimated glomerular filtration rate < 60 mL/min/1.73 m; proxy definitions were accepted. Random effect meta-analyses were used to determine the average effect of CKD on odds of CABG, stratified by ACS type and dialysis use.
Searches generated 15,138 articles, of which 13 observational studies were included (n = 1,682,207). Amongst revascularized ACS patients, those with CKD were more likely to receive CABG than those without (pooled odds ratio (OR) = 1.50 (95% confidence interval (CI) = 1.30 - 1.72). This association was stronger following ST-elevation myocardial infarction (STEMI) than non-ST-elevation ACS (NSTE-ACS) (OR: 1.54 (95% CI: 1.23 - 1.93)) versus 1.16 (1.10 - 1.23), respectively).
In high-income countries, revascularized ACS patients with CKD receive CABG (versus PCI) more frequently than those without kidney disease. However, accounting for lower use of coronary angiography in the CKD population removed this association following NSTE-ACS. Greater use of invasive angiography in those with NSTE-ACS and CKD might therefore increase access to revascularization, and thereby improve outcomes.
对于复杂多支冠状动脉疾病(CAD),冠状动脉旁路移植术(CABG)较经皮冠状动脉介入治疗(PCI)能提供更优的长期预后。慢性肾脏病(CKD)患者多支CAD患病率增加,但手术风险也更高。我们调查了在因急性冠状动脉综合征(ACS)接受血运重建的患者中,CKD是否可预测CABG与PCI在实际应用中的差异。
检索Embase、MEDLINE、Scopus和CENTRAL数据库,以识别2012年至2023年期间高收入国家中提及ACS和侵入性冠状动脉介入治疗的文章。若报告了接受血运重建的有或无CKD的ACS患者的CABG率,则纳入该文章。CKD定义为估计肾小球滤过率<60 mL/min/1.73 m²;接受替代定义。采用随机效应荟萃分析,按ACS类型和透析使用情况分层,确定CKD对CABG几率的平均影响。
检索共获得15138篇文章,其中纳入13项观察性研究(n = 1,682,207)。在接受血运重建的ACS患者中,有CKD的患者比无CKD的患者更有可能接受CABG(合并比值比(OR)= 1.50(95%置信区间(CI)= 1.30 - 1.72))。这种关联在ST段抬高型心肌梗死(STEMI)后比非ST段抬高型ACS(NSTE-ACS)更强(OR:1.54(95%CI:1.23 - 1.93)),而在NSTE-ACS中分别为1.16(1.10 - 1.23)。
在高收入国家,与无肾脏疾病的患者相比,因ACS接受血运重建且患有CKD的患者更频繁地接受CABG(而非PCI)。然而,考虑到CKD人群中冠状动脉造影的使用率较低,在NSTE-ACS后这种关联消失。因此,在NSTE-ACS和CKD患者中更多地使用侵入性血管造影术可能会增加血运重建的机会,从而改善预后。